Anna Helbok

736 total citations
16 papers, 604 citations indexed

About

Anna Helbok is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Anna Helbok has authored 16 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Molecular Biology. Recurrent topics in Anna Helbok's work include Peptidase Inhibition and Analysis (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Nanoparticle-Based Drug Delivery (5 papers). Anna Helbok is often cited by papers focused on Peptidase Inhibition and Analysis (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Nanoparticle-Based Drug Delivery (5 papers). Anna Helbok collaborates with scholars based in Austria, United Kingdom and Türkiye. Anna Helbok's co-authors include Clemens Decristoforo, Miloš Petřík, Hubertus Haas, Michael Blatzer, Elisabeth von Guggenberg, Cornelia Lass‐Flörl, Markus Schrettl, Christine Rangger, Georg Dobrozemsky and Ruth Prassl and has published in prestigious journals such as Journal of Medicinal Chemistry, International Journal of Nanomedicine and Journal of Nuclear Medicine.

In The Last Decade

Anna Helbok

16 papers receiving 595 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Helbok Austria 11 221 187 155 144 121 16 604
Zbyněk Nový Czechia 14 197 0.9× 98 0.5× 90 0.6× 95 0.7× 78 0.6× 31 484
Leonardo Lima Fuscaldi Brazil 12 179 0.8× 57 0.3× 83 0.5× 94 0.7× 32 0.3× 34 509
Philipp René Spycher Switzerland 8 101 0.5× 94 0.5× 74 0.5× 122 0.8× 107 0.9× 18 374
Ashlesha Deshpande United States 15 59 0.3× 102 0.5× 83 0.5× 266 1.8× 158 1.3× 33 725
Atsushi Shimoyama Japan 17 87 0.4× 68 0.4× 62 0.4× 292 2.0× 33 0.3× 50 674
Mary E. Neville United States 13 53 0.2× 131 0.7× 84 0.5× 301 2.1× 67 0.6× 20 795
Yakun Wan China 11 110 0.5× 69 0.4× 89 0.6× 250 1.7× 79 0.7× 17 507
Origène Nyanguile United States 13 57 0.3× 143 0.8× 67 0.4× 447 3.1× 94 0.8× 17 739
М. А. Дымова Russia 12 207 0.9× 152 0.8× 30 0.2× 171 1.2× 133 1.1× 45 610
Niels Bendsøe Sweden 16 79 0.4× 229 1.2× 143 0.9× 88 0.6× 40 0.3× 47 914

Countries citing papers authored by Anna Helbok

Since Specialization
Citations

This map shows the geographic impact of Anna Helbok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Helbok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Helbok more than expected).

Fields of papers citing papers by Anna Helbok

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Helbok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Helbok. The network helps show where Anna Helbok may publish in the future.

Co-authorship network of co-authors of Anna Helbok

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Helbok. A scholar is included among the top collaborators of Anna Helbok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Helbok. Anna Helbok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Thurner, Gudrun C., Christian Kremser, Heribert Talasz, et al.. (2020). Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles. Histochemistry and Cell Biology. 155(1). 19–73. 6 indexed citations
2.
Helbok, Anna, Sandra Bläß, Christine Rangger, et al.. (2019). Comparison of PEGylated and non-PEGylated proticles: An in vitro and in vivo study. European Journal of Pharmaceutical Sciences. 139. 105063–105063. 10 indexed citations
3.
Helbok, Anna, Christian Kremser, Gottfried Koehler, et al.. (2013). Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles. International Journal of Nanomedicine. 8. 4659–4659. 36 indexed citations
4.
Haubner, Roland, David R. Vera, Anna Helbok, et al.. (2013). Development of 68Ga-labelled DTPA galactosyl human serum albumin for liver function imaging. European Journal of Nuclear Medicine and Molecular Imaging. 40(8). 1245–1255. 32 indexed citations
5.
Rangger, Christine, Anna Helbok, Meltem Ocak, et al.. (2013). Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.. PubMed. 33(4). 1537–46. 3 indexed citations
6.
Petřík, Miloš, Gerben M. Franssen, Hubertus Haas, et al.. (2012). Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging. European Journal of Nuclear Medicine and Molecular Imaging. 39(7). 1175–1183. 99 indexed citations
7.
Helbok, Anna, Christine Rangger, Elisabeth von Guggenberg, et al.. (2011). Targeting properties of peptide-modified radiolabeled liposomal nanoparticles. Nanomedicine Nanotechnology Biology and Medicine. 8(1). 112–118. 28 indexed citations
8.
Petřík, Miloš, Hubertus Haas, Markus Schrettl, et al.. (2011). In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging. Nuclear Medicine and Biology. 39(3). 361–369. 77 indexed citations
9.
Ocak, Meltem, Anna Helbok, Christine Rangger, et al.. (2011). Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. European Journal of Nuclear Medicine and Molecular Imaging. 38(8). 1426–1435. 68 indexed citations
10.
Petřík, Miloš, Hubertus Haas, Georg Dobrozemsky, et al.. (2010). 68Ga-Siderophores for PET Imaging of Invasive Pulmonary Aspergillosis: Proof of Principle. Journal of Nuclear Medicine. 51(4). 639–645. 108 indexed citations
11.
Stollenwerk, Maria M., Christian Kremser, Heribert Talasz, et al.. (2010). Albumin-based nanoparticles as magnetic resonance contrast agents: I. Concept, first syntheses and characterisation. Histochemistry and Cell Biology. 133(4). 375–404. 16 indexed citations
12.
Ocak, Meltem, Anna Helbok, Elisabeth von Guggenberg, et al.. (2010). Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative. Nuclear Medicine and Biology. 38(2). 171–179. 16 indexed citations
13.
Petřík, Miloš, Hubertus Haas, Anna Helbok, et al.. (2010). Comparison of 68Ga-siderophores for imaging Aspergillus fumigatus infections with PET. Nuclear Medicine and Biology. 37(6). 726–726. 3 indexed citations
14.
Helbok, Anna, Clemens Decristoforo, Georg Dobrozemsky, et al.. (2009). Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals. Journal of Liposome Research. 20(3). 219–227. 58 indexed citations
15.
Helbok, Anna, Clemens Decristoforo, Martin Béhé, Christine Rangger, & Elisabeth von Guggenberg. (2009). Preclinical Evaluation of In-111 and Ga-68 Labelled Minigastrin Analogues for CCK-2 Receptor Imaging. Current Radiopharmaceuticals. 2(4). 304–310. 5 indexed citations
16.
Guggenberg, Elisabeth von, Anna Helbok, Meltem Ocak, et al.. (2009). Cyclic Minigastrin Analogues for Gastrin Receptor Scintigraphy with Technetium-99m: Preclinical Evaluation. Journal of Medicinal Chemistry. 52(15). 4786–4793. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zbyněk Nový Breakdown of academic impact, for papers by Leonardo Lima Fuscaldi Breakdown of academic impact, for papers by Philipp René Spycher Breakdown of academic impact, for papers by Ashlesha Deshpande Breakdown of academic impact, for papers by Atsushi Shimoyama Breakdown of academic impact, for papers by Mary E. Neville Breakdown of academic impact, for papers by Yakun Wan Breakdown of academic impact, for papers by Origène Nyanguile Breakdown of academic impact, for papers by М. А. Дымова Breakdown of academic impact, for papers by Niels Bendsøe
Rankless by CCL
2026